| Schedule of deferred tax assets and liabilities |
| | | | | | | | | 2025 | | 2024 | Net operating loss carry forwards | | $ | 29,960,000 | | $ | 28,438,000 | Orphan drug and research and development credit carry forwards | | | 10,298,000 | | | 9,617,000 | Equity based compensation | | | 44,000 | | | 227,000 | Intangible and fixed assets | | | 1,410,000 | | | 1,401,000 | Capitalized research and development | | | 3,497,000 | | | 2,482,000 | Lease liability | | | 37,000 | | | 69,000 | Other | | | — | | | (85,000) | Total | | | 45,246,000 | | | 42,149,000 | Valuation allowance | | | (45,216,000) | | | (42,087,000) | Net deferred tax assets | | | 30,000 | | | 62,000 | Right of use asset | | | (30,000) | | | (62,000) | Total gross deferred tax liabilities | | | (30,000) | | | (62,000) | Net deferred tax assets | | $ | — | | $ | — |
|